Propanc Biopharma, Inc.
PPCB· Nasdaq
Filed Feb 20, 2013 · 10-Q · 51 days after period end · 0001354488-13-000756
| Metric | Q2 2013 | Q2 2012 | Q2 2011 |
|---|---|---|---|
| Net Income | -$387.75K | -$2.71M | -$411.31K |
| EPS Diluted | -$0.02 | -$0.03 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Propanc Biopharma, Inc. · CIK 1517681 · Engraved from SEC EDGAR
ended Dec 31, 2012 · filed Feb 20, 2013 · 51 d after period end